Last reviewed · How we verify
insulin glargine + preprandial lispro insulin — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
insulin glargine + preprandial lispro insulin (insulin glargine + preprandial lispro insulin) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| insulin glargine + preprandial lispro insulin TARGET | insulin glargine + preprandial lispro insulin | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- insulin glargine + preprandial lispro insulin CI watch — RSS
- insulin glargine + preprandial lispro insulin CI watch — Atom
- insulin glargine + preprandial lispro insulin CI watch — JSON
- insulin glargine + preprandial lispro insulin alone — RSS
Cite this brief
Drug Landscape (2026). insulin glargine + preprandial lispro insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-preprandial-lispro-insulin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab